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ABSTRACT
Membrane proteins can associate into
larger complexes.  Examples include receptor
tyrosine complexes, ion channels, transporters
and G-protein coupled receptors (GPCRs). For
the latter, there is abundant evidence indicating
that GPCRs, assemble into complexes, through
both homo or heterodimerization.  However, the
tools for studying and disrupting these
complexes, GPCR or otherwise, are limited.
Here we have developed stabilized interference
peptides for this purpose.  We have previously
reported that tetrahydrocannabinol-mediated
cognitive impairment arises from homo- or
hetero-oligomerization between the GPCRs
cannabinoid receptor type 1 (CB1R) and 5-
hydroxytryptamine 2A (5-HT2AR) receptors.
Here, to disrupt this interaction through targeting
CB1–5-HT2A receptor heteromers in HEK293
cells and using an array of biochemical
techniques, including calcium and cAMP
measurements, bimolecular fluorescence
complementation assays, and CD-based helicity
assessments, we developed a NanoLuc binary
technology (NanoBiT)-based reporter assay to
screen a small library of aryl-carbon–stapled
transmembrane mimicking peptides produced by
solid-phase peptide synthesis. We found that
these stapling peptides have increased α-helicity
and improved proteolytic resistance without any
loss of disrupting activity in vitro, suggesting
that this approach may also have utility in vivo.
In summary, our results provide proof of
concept for using NanoBiT to study membrane
protein complexes and for stabilizing  disrupting
peptides to target such membrane complexes
through hydrocarbon-mediated stapling. We
propose that these peptides could be developed
to target previously un-druggable GPCR
heteromers.
The discovery that G-protein coupled
receptors (GPCRs) could oligomerize, termed
homo or heterodimerization, sparked an intense
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debate that has moved on from not if they can
but to why, how, how frequently and how do we
target them for therapeutic purposes.  Several X-
ray resolved GPCRs crystal structures have
revealed common dimeric interfaces stabilizing
oligomeric arrangements within the Rhodopsin-
like family receptors. Dimers having an interface
involving the transmembrane (TM) domains
TM1, TM2 and H8 appear to be a commonly
conserved organization, including the structures
of the rhodopsin, opsin, metarhodopsin II, μ and
κ opioid, and the β1 adrenergic receptors (1–6).
An additional interface involving the TM4 and
TM5 domains was also shown in the squid
rhodopsin and the β1 adrenergic receptors (2, 7).
Furthermore, the crystal structures of the
CXCR4 and μ-opioid receptors revealed a
substantial buried surface area of 850 Å2 and
1,492 Å2, respectively, comprised of the TM5
and TM6 domains (3, 8). Selective disruption of
dimers using synthetic peptides harbouring the
same amino acid sequence as the interacting TM
domains, has helped to validate and understand
the functional consequences of receptor
oligomerization, including the 2 adrenergic,
CXCR4, oxytocin and apelin receptors homo-
oligomers (9–12). Synthetic peptides have also
provided unique tools to map the interfaces and
understand the biological relevance of Class A
GPCRs heteromerization (13, 14). An additional
advantage of TM peptides is that, unlike knock-
out studies or deletions, the peptides preserve
the functional single protomers and allow one to
discriminate between those effects driven by the
interacting receptors and those derived from the
individual protomers. An example of the former
is the in vivo disruption of the cross-class
angiotensin receptor subtype 1a (AT1aR) and
secretin receptor heteromers with a TM1 AT1aR
mimetic peptide, reducing hyperosmolality-
induced drinking behaviour (13).
In cases where heteromer disruption
might serve a therapeutic purpose, it would be
advantageous to translate TM peptides not only
as tools, but into drug-like entities. Peptides in
general are considered poor drug like molecules,
although this view is changing. Efficacy is often
compromised in vivo due to a loss of secondary
structure; cellular uptake is poor and finally
peptides are highly susceptible to proteolysis.
Stapling of the peptide backbone can help to
overcome these limitations; the bioactive
conformation of the peptide is maintained, and
careful positioning and choice of staple can
result in a high affinity binder with improved
cellular uptake and stability. Stapled peptides
therefore represent an attractive approach to
developing more drug-like peptides.  For a
recent review on stapled peptides see Ali et al
(15). We have previously shown that the
undesired effect of cognitive impairment in the
presence of trans-Δ9-tetrahydrocannabinol
(THC) is driven by homo/hetero-oligomerization
between CB1 and 5-HT2A receptors (16).  To
disrupt this interaction, we developed a
NanoBiT-based assay for the screening of a
small library of aryl-hydrocarbon stapled CB1R
TM5 mimicking peptides to target CB1-5-HT2A
receptor heteromers. NanoBiT is a luciferase
based complementation assay designed to
interrogate protein-protein interactions in live
cells (17).  Using this approach we found that
stapling peptides led to increased α-helicity and
improved proteolytic resistance without any loss
of function, suggesting this approach may
improve these molecules chances in vivo.
Results
Establishing the NanoBiT system for
heteromer screening purposes
The CB1 and 5-HT2A receptor heteromer
has been recently characterized both in vivo and
in heterologous expression systems using a
broad range of biochemical approaches (16). In
the case of these heteromers, the cognitive
impairment induced by THC is abrogated after
treatment with CB1R TM5 peptides, while
maintaining its antinociceptive properties (16).
Therefore, for therapeutic purposes there needs
to be prevention of heteromer formation but
preservation of the individual protomer’s
function.  Thus, we first sought to develop a
NanoBiT-based assay for the screening of a
small library of hydrocarbon stapled CB1R TM5
mimicking peptides.  To assess whether
NanoBiT BiLC may be a suitable system to
study GPCR oligomerization, we generated
CB1R and 5-HT2AR constructs with the small
and large BiT pairs (SmBiT and LgBiT,
respectively) attached to the C-terminus end of
both receptors. A total of four fusion proteins
were generated, with Sm/LgBiT fused after the
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Gly/Ser rich flexible linker and under the control
of the herpes simplex virus thymidine kinase
gene promoter (HSV-TK) (Figure S1A). Next,
we performed conformational screenings to
assess the optimal configuration for all receptor
pairs. Accordingly, when analysing CB1R-5-
HT2AR heteromers, HEK293 cells were
transiently transfected with all possible
combinations of 5-HT2AR Lg/SmBiT and CB1R
Lg/SmBiT at two different DNA ratios (Figure
S1B). Surprisingly, none of the analysed
configurations yielded a positive interaction.
Similarly, when addressing the formation of
CB1R and 5-HT2AR homodimers, none of the
examined orientations nor DNA ratios exhibit
significant differences in comparison with the
individual receptors when expressed by
themselves (Figures S1C and D). Importantly, to
rule out whether these negative results might
reflect the unsuitability of the NanoBiT system
for the analysis of GPCR oligomerization rather
than any kind of experimental hindrance, we
analysed the known interaction between the
protein kinase A catalytic (PRKACA) and type
2A regulatory (PRKAR2A) subunits. This
protein pair positive control has been previously
optimized, with LgBiT-PRKAR2A and SmBiT-
PRKACA the optimal configuration (17). In
agreement, co-transfection of both proteins
resulted in a significant increase in the
luminescence recorded over the different
receptor ratios. Furthermore, co-transfection of
LgBiT-PRKAR2A with a non-interacting fusion
protein (HaloTag®-SmBiT) did not yield any
increase in luminescence (Figure S1E),
supporting the specificity of the detected
interaction and the suitability of this system
under our assay conditions. However, our results
do not rule out whether the complementary
fusions restrict 5-HT2AR or CB1R functionality
or if there is indeed a lack of complementation.
Importantly, it should be noted that to minimise
potential non-specific interactions all generated
constructs were under the control of the HSV-
TK promoter.
Thus, in order to address the lack of a
BiLC signal, we performed secondary
messenger signalling experiments and re-cloned
all four receptor configurations under the control
of the high-level expression cytomegalovirus
(CMV) promoter. Interestingly, all 5-HT2AR
constructs in an HSV-TK context failed to elicit
intracellular calcium release (canonical
signalling pathway downstream to the Gq/11-
coupled 5-HT2AR) after agonist stimulation (18).
However, both 5-HT2AR-LgBiT and 5-HT2AR-
SmBiT displayed similar efficacies and
potencies in comparison to the wild type (WT)
receptor when expressed under the control of the
CMV promoter (Figure S2A). Similarly, we
assessed CB1R-driven adenylate cyclase (AC)
inhibition with analogous results. Both CMV-
regulated CB1R constructs inhibited the
Forskolin (FK)-induced cAMP release with
equivalent potencies and efficacies to the WT
CB1R receptor. However, under the HVS-TK
promoter, CB1R-LgBiT failed to signal through
heterotrimeric Gi/o proteins and CB1R SmBiT
exhibited a reduced AC inhibitory activity
(~20%) when compared to WT CB1R receptor
(Figure S2B). These results indicate than the
NanoBiT fusions do not adversely affect 5-HT2A
nor CB1 receptor functionality, as the ligands
potencies and maximal efficacies are within the
wild type receptors ranges. Thus, the absence of
luciferase complementation between HSV-TK
regulated constructs most likely reflects low
levels of receptor expression due to the weaker
promoter, rather than steric hindrance of the
interacting pairs (19).
NanoBiT can be used to estimate receptor
affinities
Accordingly, as in the previous studies
illustrated in Figure 1A, we repeated the
conformational screenings with the new set of
constructs under the CMV promoter. When
analysing 5-HT2AR-CB1R heteromerization, we
detected a significant increase in the
luminescence for all receptor combinations, with
5-HT2AR-LgBiT:CB1R-SmBiT being the
optimal pair in terms of assay window (Figure
1B). To validate the specificity of the
interaction, increasing amounts of untagged 5-
HT2AR and CB1R receptors were transfected in
the presence of a fixed 5-HT2AR-LgBiT:CB1R-
SmBiT ratio. Accordingly, we observed a
decreased luminescence with increasing levels
of both untagged proteins (Figures 1E and F),
indicating that the detected interaction was not
driven by the finite affinity between the
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NanoLuc subunits. In parallel, we assessed
CB1R and 5-HT2AR homomerization with
similar results. Co-transfection of both CB1R
interacting pairs resulted in a significant increase
in luminescence that could be reverted by
increasing untagged CB1R concentrations
(Figures 1C and G). Similarly, the specific
interaction between 5-HT2AR-LgBiT and 5-
HT2AR-SmBiT was hindered when titrating
increasing concentrations of untagged 5-HT2AR
(Figures 1D and H). Importantly, when
comparing the relative intensities of these
interactions, we found that 5-HT2AR
homodimers displayed the highest luminescent
signals, followed by 5-HT2AR-CB1R heteromers
and CB1R homodimers (RLU for
5-HT2AR:5-HT2AR > 5-HT2AR:CB1R > CB1R:
CB1R). In addition, higher non-tagged 5-HT2AR
concentrations were necessary to displace
5-HT2AR homodimers (Figure 1H). However,
our results cannot discriminate whether it
reflects the relative affinities between the
interacting receptors or a more proximal
distance of the NanoBiT pairs in the C-terminus
of the receptors.  Altogether, our data strongly
supports NanoBiT BiLC as a non-destructive
and powerful tool to study GPCRs
oligomerization, providing a specific and
sensitive assay to detect these receptor
complexes in live cells.
Comparison of NanoBiT with Venus
bimolecular fluorescent complementation
In order to obtain a more comprehensive
understanding of bimolecular complementation
assays to study GPCR oligomerization, we
sought to address whether NanoBiT could
provide better results in comparison to
bimolecular fluorescent complementation. To
this end, we developed a Venus BiFC assay to
study CB1R and 5-HT2AR
homo/heteromerization. Specifically, fragments
derived from the truncated Venus fluorescent
protein at either position D155 (VC155; amino
acid residues 155 to 238) or D173 (VN173;
amino acid residues 1 to 173) where fused after
the Gly/Ser rich flexible linker to the C-terminus
of both CB1 and 5-HT2A receptors (Figure 2A).
This strategy has been extensively applied to the
study of protein-protein interactions (PPIs) and
takes advantage of Venus, a variant of the
enhanced yellow fluorescent protein (eYFP)
with improved sensitivity to chromophore
maturation under physiological temperatures
(21). Several groups have used this approach to
study GPCR oligomerization, including
heteromers between the adenosine A2A (A2AR)
and the dopamine D2 (D2R) receptors, D2R
oligomers or neuropeptide    Y Y1/Y5 receptor
heterodimers (19–21).
Attachment of both Venus hemiprotein
fragments to the 5-HT2AR C-terminal tail (5-
HT2AR-VN173 and 5-HT2AR-VC155 constructs)
did not impact receptor function, with equivalent
[Ca2+]i release dose-response curves in
comparison to the wild type receptor (Figure
S3A). Similarly, the VC155 fragments fused to
CB1R (CB1R-VC155) did not affect CB1R-
mediated cAMP release inhibition. However,
although its maximal efficacy remained
unaltered, VN1733 fusion to CB1R (CB1R-
VN173) resulted in ~10-fold reduction in WIN
55212-2 (WIN) potency (Figure S3B). Next, we
proceeded to compare both protein
complementation assays. For CB1R and
5-HT2AR homomers, BiFC experiments were
performed under the same conditions that
yielded the optimal assay windows in the
NanoBiT BiLC experiments (Figure 2). When
assessing 5-HT2AR-CB1R heteromers, both
possible receptor configurations (5-HT2AR-
VN173:CB1R-VC155 or 5-HT2AR-
VC155:CB1R-VN173) were taken into account.
Surprisingly, 24 and 48 hours after reverse
transfection, none of the analysed BiFC
combinations yielded significant fluorescent
levels (data not shown), suggesting time-
dependent protein maturation and/or folding.
Therefore, the following BiFC experiments were
performed 48 hours post-transfection (see
methods section), although BiLC assays
remained under the same setup (24 hours post-
transfection). In comparison to Venus BiFC,
NanoBiT complementation provided higher
assay windows over all the oligomeric
configurations (Figure 2). Specifically, we
observed a 20-fold increase for CB1R
homodimers, 130-fold increase for 5-HT2AR
homodimers and 9-18-fold increase for 5-
HT2AR-CB1R heteromers. Interestingly, the
relative fluorescent/luminescent intensities for
the different receptor pairs followed the same
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trend across both methods (RFU/RLU for
5-HT2AR:5-HT2AR > 5-HT2AR:CB1R >
CB1R:CB1R), suggesting that this could reflect
the affinity between these oligomeric
arrangements.
N-terminal GPCR fusions are also functional
for NanoBiT complementation
Next, we sought to test whether
N-terminal tagging might yield better assay
windows (Figure 3A). SmBiT and LgBiT fusion
to the 5-HT2AR extracellular end did not impact
function as treatment with the agonist DOI
induced maximal calcium release, although a
small reduction in DOI potency was observed in
the LgBiT-5-HT2AR construct (Figure S4A). The
homologous CB1R constructs remained
unaltered, with virtually the exact potencies and
maximal responses as the WT receptor (Figure
S4B). Next, we compared N- or C-terminal
NanoBiT-tagged receptors accounting for their
ability to reveal CB1R and 5-HT2AR
homo/heteromers. When measuring the
interaction between receptors from the same
type, NanoBiT attachment to the C-terminal
domain provided the optimal orientation for
CB1R homomers (Figure 3B).  In the case of 5-
HT2AR homomers, N-terminally tagging resulted
in a discrete but significant improvement in the
assay window at high DNA concentrations
(Figure 3B). Interestingly, the biggest difference
was observed when assessing the optimal 5-
HT2AR-CB1R heteromeric conformation, with
the N-terminal fusions providing the best results
(Figure 3C). Importantly, a ~200-fold increase
was achieved at low DNA transfected
concentrations, therefore reducing the
probability of stochastic non-specific
interactions and thus more closely mimicking
physiological expression levels. The LgBiT-
CB1R and SmBiT-5-HT2AR combination was
therefore used in all further experiments.
Design and synthesis of stapled peptides
In previous studies, we demonstrated
that 5-HT2AR-CB1R heteromers could be
selectively disrupted using synthetic peptides
mimicking the CB1R TM5 and TM6 domains
(16), fused to the HIV-TAT (GRKKRRQRRR)
cell penetrating amino acid sequence (CPS)
(23). In the same study we also showed that the
peptide mimicking CB1R TM7 did not disrupt
the heteromer. As part of our preliminary work,
we had previously identified a truncated CB1R
TM5 amino acid sequence fused to TAT
(VYAYMYILWGRKKRRQRRR) capable of
disrupting the 5-HT2AR-CB1R heteromer
(unpublished). We therefore chose to design
stapled peptides based on the amino acid
sequences of the truncated CB1R TM5 to aid
with the synthesis and purification of the
peptides as well as solubility. In addition, amino
acid sequences of 20-25 amino acid residues or
less are generally recommended for stapling (24)
Accordingly, using these structures as a
starting point, we hypothesized that shortening
their length, in combination with hydrocarbon
peptide stapling, could result in peptides with
more drug-like properties. (Figure 4A).  This
strategy, through the incorporation of -methyl-
-alkenyl amino acids, combines the
methylation of the -carbon atom together with
the introduction of a covalent side chain to side
chain cross-link, resulting in peptides with
increased -helicity and improved proteolytic
resistance (25, 26). We next evaluated where to
add the hydrocarbon staples. One major
consideration is charge.  An overall positive net
charge is favourable after staple installation to
aid with cellular uptake. The location of the
positive amino acids is also influential and if
possible should be located at the C-terminus.
Molecular modelling identified potential sites
within these TM5 peptide amino acid sequences
to introduce the hydrocarbon staple (Table 1).
The positions (facing the membrane of CB1R) to
build the stapled peptides (at i and i+3/4) are
shown in red. The TAT amino acid sequence is
shown in orange.
Peptides are often thought of as poor
drug molecules as; 1) in vivo their efficacy is
compromised due to a loss of secondary
structure; 2) they often have poor cellular
uptake and 3) they are highly susceptible to
proteolysis. Stapling of the peptide backbone is
an attractive strategy to overcome these
limitations; the bioactive conformation of the
peptide is maintained, and careful positioning
and choice of staple can result in a high affinity
binder with improved cellular uptake and
stability. Next, is the choice of staple to use.
We chose to incorporate the all-hydrocarbon
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staple for alpha-helical peptide stabilization.
This was first reported in 2000 by Schafmeister
et al. (27) and has since found use in a variety
of applications including cancer, infectious
diseases and neuroscience (28). In addition, this
staple has been shown to protect the peptide
against proteolysis as the vulnerable peptide
bonds are sequestered in the interior of the
helix. The building block for single turn
hydrocarbon stapling is the unnatural amino
acid S-pentenylalanine (Fmoc-S5-OH).
Although available commercially, we chose to
synthesise the Fmoc-protected version in-house
adapting methods reported by Jamieson and
Ryzhov (scheme 1) (29, 30). Briefly, N-
alkylation of proline with 2-fluorobenzyl
bromide gave 1 in almost quantitative yields.
This was followed by the condensation of 1
with 2-aminobenzophenone to give the chiral
auxiliary (S)-N-(2-benzoylphenyl)1(2-
fluorobenzyl)-pyrrolidine-2-carboxamide 2 (2-
FBPB). Complexation with nickel nitrate and
L-alanine gave (S)-Ni-Ala-2FBPB 3 in almost
quantitative yields. This was followed by
asymmetric alkylation to yield complex 4 in a
good yield which was subsequently
decomposed under acidic conditions to give S-
pentenylalanine 5. Finally, this was Fmoc
protected by reaction with Fmoc chloride under
basic conditions to afford Fmoc-S-
pentenylalanine 6. Following synthesis of the
unnatural amino acid we turned our attention to
the synthesis of the CB1R TM5 peptides.
Five peptides (7-11) were designed for
our study including one negative control (11)
(Figure 4A). Methionine amino acid residues
were replaced with norleucine amino acid
residues to avoid any complications or unwanted
side reactions during ring closing metathesis
reactions. Peptides were synthesised using
Fmoc-based solid-phase peptide synthesis
(SPPS) using procedures reported previously
(9). Scheme 2 outlines an example synthesis.
During assembly the Fmoc-S5-OH is
incorporated into positions separated by 2 or 3
amino acid residues as shown in Figure 4A.
Coupling times were increased from 45 minutes
to 60 minutes for the Fmoc-S5-OH and for the
residue following the olefinic unnatural amino
acid. The assembled peptides (7-10) were then
subjected to the ring-closing metathesis (RCM)
reaction whilst still on the solid support. This
was monitored using reversed-phase high
performance liquid chromatography (RP-
HPLC); note peptide 7 did not undergo the RCM
reaction. Following a final Fmoc deprotection
step, the stapled peptides were cleaved from the
solid support under acidic conditions and
subsequently purified using preparative RP-
HPLC and freeze dried from water as previously
described (30). The negative control 11 was
treated in an identical fashion with the exception
that the RCM step was omitted. Purified
peptides were analysed using analytical RP-
HPLC to assess purity and matrix assisted laser
desorption ionisation-time of flight (MALDI-
TOF) mass spectrometry to determine accurate
mass. All peptides were soluble in
water/aqueous buffer.
The administration of peptides to
disrupt GPCR interactions is relatively new,
with no available information regarding their
pharmacokinetics and/or pharmacodynamics.
Often with peptides, the in vivo efficacy is
compromised due to a loss of secondary
structure; to assess the helicity of the peptides
and whether incorporation of the staple had
increased the helical nature of the peptides we
employed circular dichroism spectroscopy.
(Figure 4B). CB1 TM5-TAT, TM6-TAT and
TM7-TAT all displayed relatively low helicity
in solution (less than ~20%). Pleasingly,
incorporation of the staples increased the helical
nature of the stapled peptides 8-10 in all cases
when compared to the TM5-TAT peptide.
Peptide 8 demonstrated the highest helicity of
58.3%. Interestingly the negative control 11,
where the olefinic amino acids are present but
not stapled, displayed an almost identical
helicity (46.0%) when compared with the
stapled version 9. When TAT is added to the
amino acid sequence 10, the helicity drops
slightly to 36.8%. A second challenge facing
protein/peptide therapies is proteolytic
degradation. Consequently, we subjected our
peptide library to in vitro trypsin, chymotrypsin
and serum proteolytic stability. When
monitoring trypsin (0.55 g/mL) degradation
kinetics (Figure 4E), a rapid proteolysis was
observed for the TM7-TAT, TM6-TAT and
TM5-TAT control peptides (55 µM each), with
half-lives ranging from 20-40 minutes.
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Pleasingly, the short-stapled CB1R TM5 amino
acid sequence harbouring the TAT amino acid
sequence 10 displayed a longer half-live, with a
2-3-fold enhancement in trypsin resistance.
Furthermore, removal of the TAT amino acid
sequence in the stapled peptides (8,9) yielded
the longest half-lives (~5 hours), as neither
lysine nor arginine amino acid residues were
available for the trypsin to cleave. This increase
in half-life was also observed for the negative
controls where the TAT amino acid sequence
was removed. Chymotrypsin proteolytic
kinetics showed similar results (Figure 4F); the
full length TM7-TAT, TM6-TAT and TM5-
TAT peptides were more susceptible to
cleavage (half-lives ranging from 20 to 30 min).
Again, a ~2-fold resistance improvement was
detected for stapled peptide 10 bearing the TAT
amino acid sequence.  Likewise, 8 and 9 were
the peptides with longer half-lives (5-6 hours)
(Figure 4F). In mouse serum, a more
physiologically relevant context, the TM7-TAT,
TM6-TAT and TM5-TAT peptides were
rapidly degraded, with a 1-hour incubation
sufficient to break down 50% of them (Figure
4G). Hydrocarbon stapling translated to an even
higher serum stability in comparison with
trypsin and chymotrypsin, with peptides 8 and 9
displaying half-lives of more than 10 hours.
These results positively correlate with the
respective helicity of each peptide, as the
reinforcement of α-helical structure limits the
peptides to adopt the extended conformation
required by proteases to hydrolyse the amide
bonds (25). Accordingly, we observed a strong
positive correlation between helicity and
proteolytic resistance (r=0.84, 0.78 and 0.87 for
trypsin, chymotrypsin and mouse serum,
respectively; Figures 4C and D). Finally, we
investigated the effects of the peptides on cell
proliferation and toxicity using a Label-Free
assay. Specifically, we analysed cell viability
based on changes in electrical impedance over
time. No statistically significant reduction in
viability of the cells was observed over a 24 or
48h period (Figure S5).
Stapled peptides are effective at disrupting
heteromers
Next we sought to test whether stapling
changed the ability of the peptides to disrupt
GPCR heteromers (schematic in Figure 5A).
Pre-incubation of HEK293 cells transiently co-
expressing LgBiT-CB1R and SmBiT-5-HT2AR
with the TM5-TAT and TM6-TAT, but not the
TM7-TAT (negative control) peptides resulted
in a decrease in the luminescence readout
(Figure 5B), corroborating the previously
reported results demonstrating the involvement
of TM5 and TM6, but not TM7, in the
heteromeric interface (16). In addition, these
results demonstrate the suitability of our
NanoBiT-based peptide screening assay and the
specificity of the detected interaction.
Next we tested whether the stapled
versions were as efficient at blocking
heteromerization (Figure 5B). When analysing
the TM5-TAT-derived peptides, compound 10
exerted a significant decrease in NanoBiT
complementation. Interestingly however,
neither the version lacking the TAT amino acid
sequence, compound 9, nor the non-staple,
compound 11, peptides induced any change.  It
was not simply length of the peptide, as the
longer stapled compound 8 also was not as
efficient as compound 10 at disrupting the
complex.  Stapling in itself did not seem to
convey an advantage as comparing compounds
9 and 11, we observed equal effects.
We next sought to understand the
disruption efficacy and the timing of compound
10’s effects on the heteromer. Treatment with
increasing concentrations of compound 10
induced a dose-dependent luminescence
decrease, with a potency in the low micromolar
range (pIC50 = 5.47 ± 0.01) (Figure 5C).
Surprisingly, the ability of compound 10 to
disrupt 5-HT2AR-CB1R heteromers was on the
order of minutes, reaching its maximal inhibitory
response approximately five minutes after
administration (Figure 5D).
Altogether, by developing a sensitive and
specific bimolecular luminescent
complementation assay we were able to screen a
small library of peptides targeting 5-HT2AR-
CB1R heteromers. In addition, covalent side
chain to chain cross-linking through hydrocarbon
peptide stapling lead us to the identification of a
small TM peptide mimetic, 10, with improved
stability, helicity and efficacy.
Discussion
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Here we have successfully provided a
proof of concept for two new tools to study
GPCR oligomerization.  First, we successfully
applied the recently developed NanoLuc binary
technology (NanoBiT) to study GPCR
oligomerization. Using this system, we validated
the previously demonstrated association of
CB1R and 5-HT2A receptors as homodimers and
their ability to form heteromers (16, 31, 32).
Second, we have demonstrated that interference
peptides can be dramatically stabilised and
shortened using aryl-carbon stapling.  These two
advances will prove useful in studying GPCR
oligomerization both in vitro and particularly in
vivo.
When adapting the NanoBiT to study
oligomerization we predicted that the small size
of the complementary fragments (18kDa and 1.3
kDa for LgBiT and SmBiT, respectively), would
minimize steric conflicts (17). In fact, agonist
potencies and maximal efficacies were
equivalent to their matched wild type receptors
under the same promoters. Apart from GLuc (19
kDa), NLuc (19 kDa) is significantly smaller in
comparison to other fluorescent/luminescent
proteins used in resonance energy transfer
(RET) or protein complementation assays
(ranging from 26 kDa for YFP up to 61 kDa for
FLuc).  In addition, no post-translational
modifications have been reported in mammalian
cells, resulting in lower energetic costs in terms
of translation, sorting and proper polypeptide
folding. Accordingly, our initial studies were
performed under the control of the low copy
number herpes simplex virus thymidine kinase
gene promoter (HSV-TK)(19). However, under
this configuration, we were not able to
quantitatively assess agonist-induced
downstream signalling pathways. Importantly,
most DNA constructs for FRET/BRET and
BiFC assays use transient expression systems
such as pcDNA3.1 vectors, with the cDNA
expressed under the control human
cytomegalovirus (CMV) immediate-early
enhancer and promoter (33, 34). Using this
strategy, we developed a microtiter-based
homogeneous assay that allowed the
identification of GPCRs oligomers in just 24
hours, reducing the chance of over-expression-
related non-specific interactions. When
comparing our NanoBiT-based dimerization
assay with Venus YFP BiFC, an approach used
to visualize more than 200 PPIs, including many
GPCR homo/heteromers (22), NanoBiT BiLC
proved far more sensitive at detecting CB1R and
5-HT2AR homodimers and 5-HT2AR-CB1R
heteromers. Presumably, the small size of the
fused fragments, NanoLuc high quantum yield
and the lack of BiFC maturation step act
synergistically to allow us to detect PPIs 24
hours after transfection under physiological
conditions. More recently, TANGO and SPARK
have been developed to study PPIs (35, 36).
Both are good approaches for larger screens or
in the case of SPARK enrichment of cell
populations by fluorescence-activated cell
sorting (FACS).  The NanoBiT system adapted
here is good for studies directly interrogating the
interactions themselves, say for mapping the
interactions themselves or testing known small
molecules as we have shown in this study.
Previously a split NanoLuc system was
published to study G-protein signalling but it
does not have the advantage of having a short
peptide portion on one of the partners as is used
in the NanoBiT system(37).
Interference peptides have been used in
multiple studies to validate or disrupt GPCR
heteromers (9, 13, 16, 38, 39).  However, these
peptides often suffer from poor
pharmacokinetics and have a poor chance of
being used or developed into drug-like entities.
To improve on the potential of such entities to
be adapted as potential therapeutics we have
stabilised a disrupting peptide using
hydrocarbon stapling.  This approach has been
used on a variety of peptide therapeutics.
However, to our knowledge stapled peptides
have not been applied to G-protein coupled
receptor oligomers.  We demonstrate here that
stapling of disrupting peptides can significantly
shorten the required length of the peptide and
dramatically improve the stability of the
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peptides.  These data support further
development of such an approach to target
GPCR oligomers in vivo.
An additional challenge presented in targeting
such complexes is that the same membrane
polypeptide can often interact with multiple
partners in different complexes, eg. Dopamine 2
receptor can interact with A2a receptor as well
as Dopamine 1 receptor, or different NMDA
subunits or AMPA subunits can make up
multiple complexes.  To date, we have not seen
that disrupting peptides are specific for a given
complex.  Our evidence here that additional
modifications can be made to these peptides
provide an opportunity for adding additional
chemical modifications that might provide more
complex specificity in the future.
Experimental procedures
1. Reagents
Unless stated otherwise, reagents and solvents
were purchased as high-grade commercial
products from Sigma-Aldrich. (R)-(+)-WIN
55212 (WIN) and (±)-2,5-Dimethoxy-4-
iodoamphetamine hydrochloride (DOI) were
purchased from Tocris Bioscience.
2. Expression vectors and cloning
Plasmids encoding the 3xHA-tagged human 5-
HT2A and CB1 receptors were obtained from the
cDNA Resource Center (#HTR02ATN01 and
#CNR010TN01, respectively; www.cdna.org).
Plasmids encoding the pGloSensor™-22F
cAMP biosensor and the complementary
NanoBiT pairs (pBiT1.1-C[TK/LgBiT],
pBiT2.1-C [TK/SmBiT], pBiT1.1-
N[TK/LgBiT], pBiT2.1-N[TK/SmBiT], LgBiT-
PRKAR2A Control Vector, SmBiT-PRKACA
Control Vector and NanoBiT® Negative Control
Vector) were purchased from Promega. The
pGP-CMV-GCaMP6s calcium sensor was a gift
from Douglas Kim & GENIE Project (Addgene
plasmid #40753). Plasmids encoding the Venus
YFP complementary pairs pBiFC-bFosVC155
and pBiFC-bJunVN173 were a gift from Chang-
Deng Hu (Addgene plasmids #22013 and
#22012, respectively). All constructs generated
in this study were generated following the
Gibson assembly method according to the
manufacturer’s instructions (Gibson Assembly®
Master Mix, NEB). Detailed information is
provided in table S1. The correct assembly of
the full genes was verified by Sanger sequencing
using universal T7 FW 5’-
TAATACGACTCACTATAGGG-3’ and BGH
RV 5’-TAGAAGGCACAGTCGAGG-3’
primers for constructs in pcDNA3.1(+)
backbone, FW 5’-
TTGGCAATCCGGTACTGTTGG-3’ and RV
5’-GCAATAGCATCACAAATTTC-3’ primers
for constructs in pBiT1.1-C [TK/LgBiT] and
pBiT1.1-N [TK/LgBiT] backbones and FW 5’-
TTGGCAATCCGGTACTGTGG-3’ and RV 5’-
GCAATAGCATCACAAATTTC-3’ primers for
constructs in pBiT2.1-C [TK/SmBiT] and
pBiT2.1-N [TK/SmBiT] backbones.
3. Cell culture and transfection
Human embryonic kidney 293 (HEK 293) cells
(ATCC® CRL-1573™) were grown in
Dulbecco’s modified Eagle’s medium
supplemented with 2 mM L-glutamine, 4.5 g/L
D-glucose, 100 μg/mL sodium pyruvate, 100
U/mL penicillin, 100 μg/mL streptomycin and
10% (v:v) heat inactivated fetal bovine serum
(Pan Biotech, Germany) at 37°C in a 5% CO2
humidified atmosphere. Cells were directly
transfected in 96-well plate format following the
reverse Lipofectamine™ 3000 (Thermo Fisher)
transfection method. Briefly, for each well, 100-
200 ng of DNA and 0.2-0.4 μL of P3000™
reagent (1:2 w:v DNA:P3000/Lipofectamine™
3000 ratio) were combined in 25 μL of Opti-
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MEM® media. The total amount of DNA/well
was kept constant with empty vector
(pcDNA3.1). In a separate tube, 0.2-0.4 μL of
Lipofectamine™ was added to 25 μL of Opti-
MEM® media. Both reaction mixes were
vortexed (2-5 sec) and incubated at RT for 5
min. After this time, the diluted DNA was added
dropwise to the Lipofectamine™-containing
tube, gently mixed by pipetting up and down and
incubated for 15 min at RT. In parallel, cells
were trypsinised according to standard
mammalian tissue culture protocols and
resuspended in complete cell culture media to
5·105 viable cells/mL. 100 μL of the cell
suspension was distributed into each well and 50
μL of the transfection mix was added on top of
the cells. The plates were then incubated at 37°C
in a 5% CO2 humidified atmosphere for 24-48
hours before performing the experiments.
4. Ca2+ and cAMP measurement
For [Ca2+]i release quantification, 50,000
cells/well were reverse transfected (see above)
with 50 ng/well of pGP-CMV-GCaMP6s
calcium sensor vector and 100 ng/well of
receptor  in poly-D-lysine coated black clear
bottom 96-well plates. 24 hours post-
transfection, the cell culture medium was
removed and the cells were starved in FBS-free
DMEM for 4 hours at 37°C in a 5% CO2
humidified atmosphere. Prior to [Ca2+]i release
measurements, the cell culture medium was
replaced by 175 μL of Ca2+ assay buffer
(145 mM NaCl, 2.5 mM KCl, 10 mM glucose,
10 mM HEPES, 2 mM CaCl2, 1 mM MgCl2;
pH 7.4) and the plates were pre-equilibrated for
1 hour in the dark at 37°C in a 5% CO2
humidified atmosphere. Immediately following
agonist addition (25 μL, 8X final concentration),
fluorescence emission intensity was recorded at
515 nm upon excitation at 488 nm in a
CLARIOstar® Multimode Plate Reader (BMG
Labtech, Germany) for 300 secs every 5 sec and
40 flashes/well at 37°C. To account for
differences in expression/cell density, an
average of 5 pre-readings were used to
normalise each well’s response.
cAMP measurements were performed as
previously described (40). Briefly, 24 hours
post-transfection, cells were incubated in FBS-
free DMEM for 4 hours at 37°C in a 5% CO2
humidified atmosphere.  Prior to cAMP
measurements, the cell culture medium was
replaced and plates were pre-equilibrated for 1
hour with cAMP assay buffer (HBSS with
24 mM HEPES, 3.3 mM NaHCO3, 1.3 mM
CaCl2, 1 mM MgSO4, 0.1% (w/v) BSA; pH 7.4)
supplemented with 0.45 mg/mL Firefly D-
Luciferin free acid. Immediately after agonist
addition, luminescence was recorded using a
CLARIOstar® Multimode Plate Reader (BMG
Labtech, Germany) with no lens (1 sec
integration time/well for 1 hour every min). To
account for differences in expression/cell
density, an average of 6 pre-readings were used
to normalise each well’s response.
5. NanoBiT BiLC and Venus BiFC assays
To assess GPCR protein:protein interactions
with the NanoBiT technology, HEK 293 cells
(50,000 cells/well) were seeded in poly-D-lysine
coated white clear bottom 96-well plates and
reverse transfected (see above) with the
plasmids encoding the complementary NanoBiT
hemiprotein fragments. For orientation
screenings, cells were transfected with two
different concentrations (50 and 100 ng/well) of
each receptor alone or in combination with the
investigated partner (see figure legends) in the
presence of empty vector (pcDNA3.1(+)) to
normalise the total amount of DNA/well. For
studies in the presence of increasing non-tagged
receptor competitors, 100 ng of each receptor
pair (CB1R LgBiT + CB1R SmBiT, 5-HT2AR
LgBiT + 5-HT2AR SmBiT and 5-HT2AR LgBiT
+ CB1R SmBiT) were co-transfected with
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increasing concentrations of the different non-
tagged constructs (from 0 to 300 ng/well) and
the total amounts of DNA/well were normalised
with empty vector (pcDNA3.1(+)). For the
screening of stapled peptides, 50 ng/well of both
LgBiT CB1R and SmBiT 5-HT2AR were reverse
transfected as previously detailed. 24 hours post-
transfection, the cell culture medium was
removed and the cells were starved in FBS-free
DMEM for 4 h at 37°C in a 5% CO2 humidified
atmosphere. The cell culture media was replaced
by 100 μL of NanoBiT assay buffer (same as for
cAMP measurements) and the plates were pre-
equilibrated for 1 hour at RT in the dark. When
peptide pre-treatment was required, peptides
were added over this pre-equilibration step,
unless when studying inhibition kinetics, in
which the peptides were administered
immediately after the baseline luminescence
recording. 25 μL/well of a 5X solution of the
Nano-Glo® Live cell reagent containing the
cell-permeable furimazine substrate dissolved in
Nano-Glo® LCS Dilution buffer were added
and the luminescence was immediately
monitored in CLARIOstar® Multimode Plate
Reader (BMG Labtech, Germany) with no lens
(1 sec integration time/well for 1 hour every
min).
For BiFC experiments, HEK 293 cells growing
at ~80% confluence in 6-well/plates were
transfected with Lipofectamine™ 3000
according to manufacturer’s instructions with
1.5 μg/well of both Venus YFP complementary
plasmids or the corresponding individual
receptor constructs. The total amount of
DNA/well was kept constant with empty vector
(pcDNA3.1(+)). 24 hours post-transfection, the
cells were trypsinised according to standard
mammalian tissue culture protocols and 5·105
viable cells/mL were seeded in poly-D-lysine
coated black clear bottom 96-well plates and
incubated at 37°C in a 5% CO2 humidified
atmosphere O/N. 48 hours post- transfection, the
cell culture medium was removed and the cells
were starved in FBS-free DMEM for 4 h at 37°C
in a 5% CO2 humidified atmosphere. Prior to
fluorescence measurements, the cell culture
media was replaced with 100 μL of NanoBiT
assay and the plates were pre-equilibrated for 1
hour at RT in the dark. Venus YFP fluorescence
was measured at 530 nm (550-50 nm and 517.2
nm dichroic filter) upon excitation (40
flashes/well) at 489 nm (497-15 nm) in a
CLARIOstar Multimode Plate Reader (BMG
Labtech, Germany) at 25°C.
6. Cell proliferation and toxicity assays
The iCELLigence Real-Time Cell Analyser
(RTCA) instrument (Roche Diagnostics GmbH
and ACEA Biosciences) was used to analyse cell
viability based on changes in electrical
impedance over time (defined as cell index; CI).
Prior to the experiment, background CI levels of
the 8-well E plate (ACEA Biosciences, USA)
were measured after the addition of 200 μL/well
of pre-warmed complete cell culture medium
(see below). Immediately after, 200 μL of the
cellular suspension (2.5 x 105 viable HEK 293
cells/mL) were distributed in each well and
cellular impedance was continuously monitored
(time intervals are indicated in the respective
figure) at 37°C in a 5% CO2 humidified
atmosphere. After 24 hours, the E-plates were
removed for peptide treatment (4 μM),
immediately returned back to the RTCA
analyser and CI changes were monitored under
the same conditions over the next 48 hours.
Normalised cell index (NCI) refers to the ratio
between the CI values and CI from the time
point immediately prior to ligand addition.
7. Data analysis
Dose-response curves were fitted using a four-
parameter logistic nonlinear regression mode.
Peptide stability data was fitted using a
nonlinear regression mode for dissociation
kinetics. All statistical tests, curve fitting and
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graphing were performed using GraphPad Prism
8 (GraphPad Software, La Jolla, CA).
Information on the statistical test, significance
and experimental replicates are provided in the
figure legends.
8. Positioning of the staple position
We previously published a model of the CB1–5-
HT2A heterodimer (16).  Using this model we
identified the amino acids of CB1R TM5 that
would be facing outward from the CB1R
receptor and using an i +3 we located the amino
acids on which to place the staples using the
logic that the staples should be on the opposite
side of the helix from the interface of the two
receptors.
9. Synthesis of the unnatural amino acid
9.1 General procedure
All experiments were run under an atmosphere
of nitrogen, using anhydrous solvents. All
chemicals were purchased from Sigma-Aldrich.
Analytical thin layer chromatography was
performed on Merck Kieselgel 60 F254 plates
with visualization by ultraviolet light. Flash
chromatography was performed on an Isolera™
Prime (Biotage AB, Sweden). Melting points are
uncorrected and were obtained in open
capillaries using Electrothermal Melting Point
Apparatus. NMR Spectra were recorded on
Bruker DPX (1H, 400 MHz; 13C, 100 MHz; 19F,
376 MHz) spectrometers for CDCl3 solutions.
NMR chemical shifts (δ) are given in parts per
million (ppm) relative to CDCl3 at 7.26 ppm and
coupling constants (J) are reported in Hz.
Spectral data is reported as follows: chemical
shift, integration, multiplicity (s, singlet; d,
doublet; t, triplet; m, multiplet). Optical rotations
were measured on a JASCO P1010 polarimeter.
High resolution mass spectra were recorded at
The National Mass Spectrometry Facility &
Service at Swansea University Medical School,
UK.
9.2 Synthesis of (S)-1-(2-
fluorobenzyl)pyrrolidine-2-carboxylic acid 1
L-proline (8 g, 69.5 mmol) was added to a
solution of freshly ground potassium hydroxide
(11.7 g; 3 equiv.) previously dissolved in
isopropyl alcohol (90 mL) at 40 °C. As soon as
the solution became transparent, 2-fluorobenzyl
bromide (8.5 mL) was added dropwise and the
solution stirred for 18h at 40 °C. Aqueous
hydrochloric acid (37%) was added dropwise to
the mixture until the solution reached pH 5-6, as
determined using pH indicator strips. The
suspension was then cooled in an ice bath for 15
min, filtered and the precipitate thoroughly
washed with isopropyl alcohol. All filtrates were
combined and concentrated in vacuo to give (S)-
1-(2-fluorobenzyl)pyrrolidine-2-carboxylic acid
1 as a pale orange sticky compound (13.29 g,
93%). For analytical purposes, a small amount
of BP was washed with acetone and
concentrated in vacuo to afford a yellow solid
powder of 1. m.p: 79-81 °C; [α]D20 -23.9 (c 0.1
in MeOH); 1H NMR (400 MHz, CDCl3) δ 7.95
(1H, br s, OH), 7.42 (1H, d, J = 6.72 Hz, Ar–
CH), 7.29-7.24 (1H, m, Ar–CH), 7.09 (1H, appt,
J = 7.48 Hz, Ar–CH), 7.03 (1H, m, Ar–CH),
4.25 (1H, d, J = 13.04 Hz, N–CH2), 3.86 (1H, d,
J = 13.05 Hz, N–CH2), 3.74 (1H, dd, J = 7.83,
6.3 Hz α-CH), 3.29 (1H, m, δ-CH2), 2.49 (1H,
dd, J = 9.15, 17.85 Hz, δ-CH2), 2.21–2.01 (2H,
m, β-CH2), 1.89–1.72 (2H, m, γ-CH2). 13C NMR
(100 MHz; CDCl3) δ 175.41, 162.61, 132.76,
130.19, 124.36, 121.9, 115.9, 67.75, 52.83,
50.84, 29.12, 22.62. Additional peaks arise from
rotamers at 130.11, 121.8 and 115.4; 19F NMR
(376 MHz; CDCl3) −116.99; HRMS-ESI
calculated for C12H15NO2F [M + H]+ 224.1087,
found 224.1081.
9.3 Synthesis of (S)-N-(2-benzoylphenyl)-1-(2-
fluorobenzyl)pyrrolidine-2-carboxamide 2
(S)-1-(2-fluorobenzyl)pyrrolidine-2-carboxylic
acid 1 (3.3 g, 14.73 mmol) was dissolved in
CH2Cl2 (35 mL) at 0 °C. Methanesulfonyl
chloride (5 mL, 14.73 mmol) and N-
methylimidazole (2.6 mL, 32.4 mL) was added
in a dropwise manner. After 5 minutes, 2-
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aminobenzophenone (2.62 g, 13.3 mol) was
added, the ice bath removed, and the reaction
mixture heated to 50 °C for 14h.  Saturated
aqueous sodium hydrogen carbonate solution
(30 mL) was added. The two layers were
separated, and the aqueous layer extracted with
CH2Cl2 (3x 30 mL). The organic extracts were
combined, dried over sodium sulphate, filtered
and concentrated in vacuo. Purification by flash
column chromatography (SiO2 eluted with 15%
ethyl acetate-hexane) gave the title compound 2
as a pale-yellow powder (2.94 g, 49.4%). m.p:
89-91 °C; [α]D20 -124.1 (c 0.25 in MeOH); 1H
NMR (400 MHz, CDCl3) δ 11.43 (1H, s, NH),
8.56 (1H, dd, J = 8.19, 1.0 Hz, Ar–CH), 7.78–
7.76 (2H, m, Ar–CH), 7.62 (1H, td, J = 7.41, 1.1
Hz), 7.55–7.48 (5H, m, Ar–CH), 7.11 (2H, m,
Ar–CH), 6.94 (1H, td, J = 7.51, 1.2 Hz, Ar–CH),
6.80 (1H, dt, J = 9.22, 1.2 Hz, Ar–CH), 3.91
(1H, d, J = 13.52 Hz, N–CH2), 3.74 (1H, dd, J =
12.97, 1.2 Hz, N–CH2), 3.36 (1H, dd, J = 10.18,
4.46 Hz, α-CH), 3.24 (1H, m, β-CH2), 2.48 (1H,
dd, J = 9.08, 16.54 Hz, β-CH2), 2.26 (1H, m, δ-
CH2), 1.96 (1H, d, J = 3.66, δ-CH2), 1.89–1.74
(2H, m, γ-CH2).; 13C NMR (100 MHz; CDCl3) δ
198.1, 174.65, 160.02, 139.19, 138.8, 133.5,
132.7, 131.9, 130.3, 129.11, 129.03, 128.45,
125.8, 125.17, 125.02, 124.08, 122.5, 121.7,
115.42, 115.2, 68.11, 53.94, 52.2, 31.27, 24.45;
19F NMR (376 MHz; CDCl3) −117.6; HRMS-
ESI (calculated for C25H24N2O2F [M + H]+
403.1822, found 403.1816
9.4 Synthesis of Ni-Ala-FBPB 3
(S)-N-(2-Benzoylphenyl)-1-(2-
fluorobenzyl)pyrrolidine-2-carboxamide 2 (2.0
g, 4.96 mmol) was dissolved in methanol (55
mL) at 50 °C. Ni(NO3)2·6H2O (2.9 g, 9.93
mmol) and L-alanine (0.89 g, 9.93 mmol) were
added to the reaction mixture and after 3
minutes, freshly ground potassium hydroxide
(1.95 g, 34.57 mmol) was added and the mixture
was heated to 70 °C for 1.5h.The reaction
mixture was cooled on the room temperature and
concentrated. The residue was taken up in
distilled water (50 mL) and extracted with
EtOAc (3 x 50 mL). The combined organic
layers were washed with brine solution (3 x 150
mL), dried over sodium sulphate, filtrated,
concentrated in vacuo and extensively washed
with CHCl3 to give the title compound 3 as a red
crystalline solid (2.61 g, 99%). m.p: 279–281 °C
(lit1: 283–285 °C); [α]D20 +3432.9 (c 0.05 in
CHCl3) (lit1: +3126.6 (c 0.05 in CHCl3); 1H
NMR (400 MHz, CDCl3) δ 8.30 (1H, td, J =
7.52, 1.72 Hz, Ar–CH), 8.11 (1H, d, J = 8.52
Hz, Ar–CH), 7.53–7.49 (2H m, Ar–CH), 7.45
(1H, d, J = 7.46, Ar–CH), 7.24–7.20 (2H, m,
Ar–CH), 7.19–7.12 (2H, m, Ar–CH), 7.05 (1H,
appt, J = 9.49 Hz, Ar–CH), 6.95 (1H, d, J =
7.39, Ar–CH), 6.69–6.62 (2H, m, Ar–CH), 4.40
(1H, d, J = 13.06, N–CHH), 3.90 (1H, q, J =
7.01 Hz, α-C(Me)H), 3.82 (1H, d, J = 13.0Hz,
N–CHH), 3.69 (1H, d, J = 6.71, β(Pro)-CHH),
3.51–3.46 (2H, m, α(Pro)-CH, γ(Pro)-CHH),
2.81 (1H, m, δ(Pro)-CHH), 2.56 (1H, m, δ(Pro)-
CHH), 2.21 (1H, dt, J = 12.65, 6.50 Hz, γ(Pro)-
CHH), 2.05 (1H, td, J = 11.59, 6.03 Hz, β(Pro)-
CHH), 1.58 (3H, d, J = 7.03 Hz, CH3); 13C NMR
(100 MHz, CDCl3) δ 180.49, 180.1, 170.35,
142.06, 134.21, 133.47, 133.2, 132.18, 131.29,
128.9, 127.5, 127.23, 126.62, 124.55, 123.92,
120.87, 120.87, 120.33, 120.30, 116.24, 116.02,
70.33, 66.64, 57.07, 55.6, 30.7, 24.16, 21.84; 19F
NMR (376 MHz, CDCl3) δ −112.66; HRMS-
ASAP calculated for C28H27N3O3FNi [M + H+]
532.1381, found 530.1357
9.5 Synthesis of S5-Ni-Ala-FBFB 4
Finely ground sodium hydroxide (0.31 g, 7.52
mmol) was added to DMF (15 mL) under a
nitrogen atmosphere with stirring at 5 °C.  Ni-
Ala-FBPB 3 (1 g, 1.88 mmol) was added and the
reaction mixture stirred for 5 min. After the
solution darkened in colour, the ice bath was
removed and solution of 1-bromo-4-pentene
(0.873 g, 5.64 mmol) was added to the reaction
mixture. The reaction mixture was heated to 50
°C and left to stir for 1h. Upon completion of the
reaction, the mixture was quenched with
distilled water (10 mL). The mixture was
concentrated in vacuo, taken up in distilled
water (15 mL) and extracted with CH2Cl2 (3 x
20 mL). The combined organic extracts were
washed with aqueous lithium chloride solution
Stapled TM peptides modulate GPCR oligomers
14
(5%, 3 x 40 mL) to thoroughly remove any
DMF residue followed by brine (3 x 40 mL).
The mixture was then dried over sodium sulfate
and concentrated in vacuo. Purification by flash
column chromatography (EtOAc-hexane=1:1)
gave the title compound 4 as a deep red-orange
solid (0.69 g, 61%). m.p: 196-198 °C (lit2:190–
192 °C) [α]D20 +2201.1 (c 0.05, CHCl3)
(lit2:+2271.2 (c 0.05, CHCl3); 1H NMR (400
MHz, CDCl3) δ 8.29 (1H, td, J = 7.4, 1.0 Hz,
Ar–CH), 8.03 (1H, d, J = 8.5 Hz, Ar–CH), 7.51–
7.44 (2H, m, Ar–CH), 7.38 (1H, m, Ar–CH),
7.33 (1H, m, Ar–CH), 7.29 (1H, m Ar–CH),
7.20 (1H, appt, J = 7.4 Hz, Ar–CH), 7.16 (1H,
ddd, J = 8.4, 6.2, 2.2 Hz, Ar–CH), 7.06 (1H,
appt, J = 9.1 Hz, Ar–CH), 6.97 (1H, d, J = 7.6
Hz, Ar–CH), 6.68–6.61 (2H, m, Ar–CH), 5.86
(1H, ddt, J = 17.0, 10.3, 6.5 Hz, CHCH2), 5.08
(1H, dd, J = 17.0, 1.0 Hz, CHCH2cis), 5.02 (1H,
d, J = 10.3 Hz, CHCH2trans), 4.52 (1H, d, J =
13.1 Hz, N–CHH), 3.95 (1H, d, J = 13.1 Hz, N–
CHH), 3.60 (1H, dd, J = 9.9, 6.5 Hz, α(Pro)-
CH), 3.41 (1H, dd, J = 10.7, 6.4 Hz, δ(Pro)-
CHH), 3.26 (1H, m, β(Pro)-CHH), 2.78 (1H, m,
γ(Pro)-CHH), 2.52 (1H, m, γ(Pro)-CHH), 2.40
(1H, m, γ-CHH), 2.17–1.98 (5H, m, δ-CH2, γ-
CHH, δ(Pro)-CHH, β(Pro)-CHH), 1.75–1.62
(2H, m, β-CH2), 1.23 (3H, s, CH3); 13C NMR
(101 MHz, CDCl3) δ 182.38, 180.15, 172.4,
141.5, 137.83, 136.44, 134.2, 133.45, 131.62,
131.31, 130.32, 129.41, 128.77, 127.97, 127.34,
126.94, 124.51, 124.0, 120.8, 120.33, 116.28,
116.0, 115.44, 78.1, 70.15, 56.67, 55.86, 39.78,
33.71, 30.54, 29.6, 25.27, 23.25; 19F NMR (376
MHz, CDCl3) δ −113.7; HRMS-ESI calculated
for C33H35N3O3FNi [M+H]+ 598.2016, found
598.6649.
9.6 Synthesis of S-pentenylalanine 5
3M hydrochloric acid (3.1 mL, 24 equivalent)
was warmed to 70°C.   A solution of S5-Ni-Ala-
FBFB 4 (300 mg) dissolved in methanol (25
mL) was added drop wise to pre-warmed HCl.
In 5 min, a colour change from red to
transparent green/yellow was observed. The
mixture was left stirring for an additional 20 min
and then cooled to room temperature. After
removing the methanol in vacuo, the residue was
taken up in water (20 mL) and extracted with
DCM (3 x 20 mL). The organic extracts were
combined, dried (MgSO4) and concentrated in
vacuo to reclaim 2. A few drops of 1M NaOH
were added to the green aqueous solution to
precipitate Ni-salts. After 2 min centrifugation at
600 rpm, the filtrate was decanted and after
removal of the water in vacuo, S-pentenylalanine
5 was isolated as a white powder (70 mg, 89%).
m.p: 242-244°C (lit2: 250–252 °C) [α]D20 +3.09
(c 0.05, MeOH) (lit2: +3.22 (c 0.05, MeOH,
25°C)); 1H NMR (400 MHz, D2O) δ 5.74 (1 H,
dd, J = 10.23, 17.08 Hz, CHCH2), 4.94 (2 H, m,
CHCH2), 1.99 (2 H, d, J = 6.55 Hz, δ-CH2), 1.85
(1 H, m, β-CHH), 1.74 (1 H, m, β-CHH), 1.50–
1.35 (4 H, m, CH3, γ-CHH), 1.26 (1 H, m, γ-
CHH); 13C NMR (100 MHz, D2O) δ 177.0,
138.7, 115, 61.6, 36.7, 32.8 , 22.5, 22.5; HRMS-
ESI (calculated for C8H16NO2 [M+H+] 158.1181,
found 158.1562.
9.7 Fmoc-S-pentenylalanine 6
Potassium carbonate (70 mg, 0.51 mmol) and S-
pentenylalanine 5 (40 mg, 0.25 mmol) was
dissolved in water (1 mL) and cooled to 0 °C.
pH was routinely checked with the pH indicators
and after confirming the basic conditions, Fmoc-
Cl (100 mg, 0.38 mmol) was dissolved in
dioxane (1.4 mL) and added to the reaction
mixture over 10 min. The reaction was then
warmed to the room temperature and stirred for
36h. An excess volume of water was added and
the mixture extracted with ethyl acetate (2 x 10
mL). The combined organic phases were then
extracted with saturated bicarbonate solution (2
x 20 mL) and the aqueous layer acidified to pH
1 with 6M HCl. The combined aqueous phases
were then extracted with EtOAc (3 x 20 mL).
The organic phases were combined, dried
(MgSO4) and concentrated in vacuo. Purification
by column chromatography (SiO2 eluted with
MeOH:CH2Cl2:AcOH (97:2:1) gave Fmoc-S-
pentenylalanine 6 as a white powder (35mg,
21%). m.p: 225-227 °C [α]D20 +3.6 (c 1.0,
MeOH) (lit2: +3.5 (c 1.0, MeOH, 25°C); 1H
NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 7.3, 3.7
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Hz, 2H), 7.59 (s, 2H), 7.45 – 7.38 (m, 2H), 7.35
– 7.28 (m, 2H), 5.75 (s, 1H), 5.46 (s, 1H), 4.99
(t, J = 14.2 Hz, 2H), 4.42 (s, 2H), 4.22 (s, 1H),
2.05 (s, 2H), 1.86 (s, 1H), 1.60 (s, 3H), 1.27 (s,
2H). 13C NMR (101 MHz, CDCl3) δ 179.18,
154.82, 143.81, 141.37, 138.02, 127.72, 127.09,
125.02, 120.01, 115.10, 66.56, 59.76, 47.23,
36.22, 33.39, 23.29; HRMS-ESI (calculated for
C23H26NO4 [M+H+] 380.1862, found 380.1860.
10. Synthesis and purification of the TM
Peptides
Transmembrane (TM) peptides were synthesized
on a fully automated Syro I (Biotage AB,
Sweden) instrument using standard procedures
for Fmoc-solid phase peptide synthesis on a 100
mg preloaded H-Arg(Pbf)-HMPB NovaPEG or
H-Phe-HMPB NovaPEG resin (Merck
Millipore, Darmstadt, Germany) with the resin
loading of 0.48 mmol/g or 0.63 mmol/g,
respectively, as a solid support. The preloaded
arginine resin was swollen in DMF for 20
minutes and checked for potential clumping
since clumped resin may impact the synthesis.
After the swelling, coupling was achieved using
4 equivalents of the following: Fmoc-protected
amino acid, HOBt and HBTU and 8 equivalents
of DIPEA in NMP. Each coupling reaction was
left for 45 minutes and performed twice to
ensure complete coupling. Fmoc deprotection
was achieved using 40% piperidine in DMF (3 x
1.5 mL). After final incorporation of the last
amino acid, the Fmoc group was removed and
the resin was washed thoroughly with DMF,
DCM and 1:1 DCM:MeOH to remove any
residual DMF and dried in vacuo. Cleavage
from the solid support was carried out using
TFA/water/EDT/TIPS (v/v/v/v = 94/2.5/2.5/1,
10 mL/0.1 g resin) in case of TM5-7 for 3h. For
peptides 7-11 TFA/water/TIPS (v/v/v =
95/2.5/2.5, 10 mL/0.1 g resin) was used. The
resin was washed with TFA (10 mL), combined
with the cleavage cocktail and concentrated in
vacuo. The crude peptide was precipitated with a
10-fold excess of cooled (-20°C) diethyl ether
leaving a white precipitate.
Following crude peptide isolation, the peptides
were dissolved in methanol (40 mL), filtered and
purified by preparative RP-HPLC (Agilent 1200
Infinity) using an Aeris PEPTIDE 5m XB-C18
column, 150 x 21.2 mm with a gradient of 95:5
water:MeOH with 0.05% TFA to 5:95
water:MeOH over 15 min returning to 95:5
water:MeOH over 5 min at a flow rate of
20mL/min at the detection wavelength of 214
nm. Analytical RP-HPLC was then used to
assess the purity of the products after the
purification and was performed on an Agilent
1200 using an Aeris Peptide 5m XB-C18
column, 150 x 4.6 mm with the same conditions
as above. Following purification, the peptides
were concentrated, resuspended in distilled
water and lyophilized. Mass analysis was
performed to determine the identities of TM
peptides by MALDI-TOF mass spectrometry,
using sinapinic acid as the ionization matrix.
11. Synthesis and purification of the stapled
peptides
Peptides were synthesized on a Syro I fully
automated peptide synthesizer using Rink amide
LL 100-200 mesh resin (0.36 mmol∕g), at 36
μmol scale as described above. Coupling
frequency and incubation times were 2 × 45 min
for standard amino acid residues, 2 × 60 min for
the olefinic non-natural amino acid 6, and 2 × 60
min for the residue following a non-natural
amino acid. After the automated synthesis, the
ring-closing metathesis was performed on the
peptide while still on the solid support in a
disposable fritted reaction vessel. The peptide
resin was cyclized in the presence of Grubbs
catalyst second-generation catalyst (10 mM) in
anhydrous 1,2-dichloroethane (DCE) for 4h at
room temperature. Completeness of the ring-
closing metathesis (RCM) reaction was
monitored by HPLC. The resin- bound peptide
was washed with DCE and then with DCM,
DCM:MeOH (1:1) and dried under vacuum. The
Fmoc group was removed with 30% piperidine
in DMF (2 x 10 min), washed with DMF, DCM,
DCM:MeOH (1:1) and dried under vacuum. The
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stapled peptides were cleaved from the solid
support by treatment with TFA:H2O:TIPS
(95/2.5/2.5) for 2-3h at room temperature. The
resin was washed with TFA (10 mL), combined
with the cleavage cocktail and concentrated in
vacuo. The crude peptide was precipitated with a
10-fold excess of cooled (-20°C) diethyl ether
leaving a white precipitate. Purification, HPLC
and MALDI-TOF analysis were performed as
above.
12. Monitoring the RCM reaction
An analytical test for monitoring the progress of
the RCM reaction was performed in a similar
manner as described by Young Woo et al.(24) A
50 μL aliquot of resin suspension was taken out
of the reaction and washed with 200 μL of
anhydrous DCE under nitrogen bubbling.  After
that initial wash, the reaction solution was
washed with DCM and DCM:MeOH (1:1),
cleaved with 60 μL cleavage cocktail
(TFA:H20:TIS (95/2.5/2.5) for 40 min, resin
removed, TFA evaporated and the peptide
precipitated with cold  diethyl ether. The pellet
was left to air dry before dissolving it in 25 μL
of 95:5 water:MeOH with 0.05% TFA and
analysed using analytical RP-HPLC.
13. CD helicity measurements
CD spectra were recorded on a Jasco J-810 with
a total of three scans from 195 to 260 nm in 0.5
nm increments. The averaged scans were
collected at the scanning speed of 200 nm/min
using a 1-mm path length cell. Peptides were
prepared as described in Greenfield’s
protocol(41), dissolved in MilliQ deionized
water with the target concentration between 30
to 50 μM with the exact concentration then
confirmed using a BCA Protein Assay Kit
according to the manufacture’s protocol. The
CD Spectrum of the MilliQ Water was
subtracted from the spectrum of the sample.
The Jasco J-810 generates the raw output in
ellipticity and is measured in millidegrees
(mdeg). This was first converted to molar
ellipticity [θ] with units of × . Once
the precise concentration was confirmed, the
molar ellipticity [θ] was calculated as:[ ] = × 10× ×
Where c is the sample concentration (μM), l is
the path length (mm), n is the number of
peptides bonds (calculated as amino acid
residues – 1) and θobs is the observed ellipticity
(mdeg). To calculate the % of helicity, the mean
residue ellipticity [MRW] and θMAX were
calculated according to Forood et al.(42) and
others:(43–45)
where θ222 is molar ellipticity at 222nm, c is
molar concentration of the peptide and n is a
number of amino acids residues.
where T is the temperature (273 K) and k the
number of non-hydrogen-bonded peptide
carbonyl. According to Shepherd et al. (44),
intramolecular hydrogen bonds are characteristic
of alpha helicity so inclusion/exclusion of N-
terminal acetyl group or C-terminal amide group
effects k. For Ac-[Peptide]-NH2 k=3; H-
[Peptide]-NH2 k=2 and for H-[Peptide]-OH k=1.
Percent helicity was then calculated as:
14. Proteolytic Stability Studies
Stability against trypsin: To a 100 μL of peptide
solution (100 μM, dissolved in ammonium
bicarbonate buffer, pH 7.5), 60 μL ammonium
bicarbonate buffer (pH 7.5) was added, together
with temperature-equilibrated (37± 1 C) 20 μL
trypsin (5 μg/mL) from porcine pancreas
(Sigma, 13,000-20,000 BAEE units/mg protein).
Peptides were incubated for 15, 30, 60, 120, 240
[ ] = (−44000 + 250 ) × (1 − )
% ℎ = [ ][ ] × 100
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and 480 min and then MeOH (HPLC Grade) +
0.05% TFA was added. The samples were then
centrifuged (15,000 rpm) and the supernatant
analyzed, using Fmoc-Gly (10 μL, 0.2 mM) as
an internal standard. The digestion at each time
points was repeated three times to give the
average values along with standard deviations.
The amount of intact peptide remained in the
mixture was quantified by RP-HPLC. The
experiment was repeated twice on different days.
Stability against chymotrypsin: To a 100 μL of
peptide solution (100 μM, dissolved in
ammonium bicarbonate buffer, pH 7.5), 60 μL
ammonium bicarbonate buffer (pH 7.5) was
added, together with temperature-equilibrated
(37± 1 C) 20 μL α-chymotrypsin (5 μg/mL)
from bovine pancreas (Sigma, Type II, activity >
40 units/mg protein). Peptides were incubated
for 15, 30, 60, 120, 240 and 480 min and then
MeOH (HPLC Grade) + 0.05% TFA was added.
The samples were then centrifuged (15,000 rpm)
and supernatant analyzed in a similar manner as
described above. The experiment was repeated
twice on different days.
Stability in the mouse serum: To 200 µL of fresh
non-sterile mouse serum was added 25 µL of
peptide solution (100 µM, dissolved in
ammonium bicarbonate buffer, pH 7.5,
containing 10% DMSO), and the mixture was
incubated at 37 ºC. At the specified time, an
aliquot of incubation mixture was withdrawn
and quenched by addition of equal volume of
15% trichloroacetic acid in acetonitrile to
precipitate out serum proteins over ice for 30
min. The mixture was then centrifuged at 13,500
rpm for 10 min, and the supernatant was
collected and analyzed by HPLC in a similar
manner as described previously. The experiment
was repeated twice on different days.
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Peptide Amino Acid Sequence
CB1R TM5 ETYLMFWIGVTSVLLLFIVYAYMYILW GRKKRRQRRR
CB1R TM5a VLLLFIVYAYMYILW
CB1R TM5b VLLLFIVYAYMYILW
CB1R TM5c VYAYMYILW
CB1R TM5d VYAYMYILW
Table 1: Potential sites within the CB1R TM5 peptide amino acid sequence to introduce the hydrocarbon
staple were identified based on a previously published molecular model (see Methods). The positions
(facing the lipids) to build the stapled peptides (at i and i+3/4) are shown in red. The TAT amino acid
sequence is shown in orange.
Scheme 1: Synthesis of the Fmoc protected unnatural amino acid S-pentenylalanine (Fmoc-S5-OH).
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Scheme 2: Synthesis of stapled peptide 8.
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Figure 1. NanoBiT complementation can be used to estimate oligomer affinities. (A) Schematic
representation of the CMV-promoter NanoBiT fusion proteins. HEK 293 cells were transiently
transfected with all possible orientations of LgBiT and SmBiT C-terminal fusions at two different DNA
ratios (50 or 100 ng receptor/well) to assess 5-HT2AR-CB1R heteromers (B) or CB1R (C) and 5-HT2AR
(D) homomers. Disruption of CB1R (E) and 5-HT2AR (F) homomers and  5-HT2AR-CB1R heteromers (G
and H) was assessed in the presence of increasing un-tagged receptor concentrations (see figure legends).
In B-D, data are mean AUC (RLU) ± SEM (n = 3). In (B), statistical significance was evaluated by one-
way analysis of variance (ANOVA) followed by Bonferroni post hoc tests showing significant effects for
CB1R LgBiT + 5-HT2AR SmBiT (50ng) against the same configuration at 100 ng/well or each equivalent
individual construct (***p ≤0.001, ****p ≤0.0001), for CB1R LgBiT + 5-HT2AR SmBiT (100ng) over
each equivalent individual construct (####p ≤0.0001), for CB1R SmBiT + 5-HT2AR LgBiT (50ng) over
the same configuration at 100 ng/well or each equivalent individual construct ($p≤0.05, $$$$p ≤0.0001)
and for CB1R SmBiT + 5-HT2AR LgBiT (100ng) over each equivalent individual construct (££££p
≤0.0001). In C and D, statistical significance was evaluated as in B, showing significant effects for CB1
SmBiT + CB1R LgBiT (50) or 5-HT2AR SmBiT + 5-HT2AR LgBiT (50) over the same configuration at
100 ng/well or each equivalent individual construct (***p ≤0.001, ****p ≤0.0001) and for CB1 SmBiT +
CB1R LgBiT (100) or 5-HT2AR SmBiT + 5-HT2AR LgBiT (100) over each individual construct (####p
≤0.0001). In E-H, values are mean ± SEM (n ≥ 3) of percentage of luminescence normalised to 0 ng of
non-tagged competitor. For each condition, statistical significance was evaluated by one-way analysis of
variance (ANOVA) followed by Bonferroni post hoc tests showing significant effects over 0 ng of non-
tagged competitor (**p ≤0.01, ***p ≤0.001, ****p ≤0.001). CMV, human cytomegalovirus immediate-
early promoter.
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Figure 2. Comparative analysis of NanoBiT with Venus Bimolecular Fluorescent complementation
(BiFC). (A) Schematic representation of the CMV-driven Venus YFP BiFC fusion proteins. In (B), HEK-
293 cells were transiently transfected with all possible Venus YFP complementary orientations and
compared to its equivalent NanoBiT BiLC pairs to assess CB1R and  5-HT2AR homomers and 5-HT2AR-
CB1R heteromers. Data are mean ± SEM (n ≥ 3) of fold change, calculated as ratio between each
condition and the individual receptor construct with the highest luminescence/fluorescence values.
Statistical significance was evaluated by unpaired t-tests between groups followed by Holk-Sidak
corrections for multiple comparison (****p ≤0.0001). CMV, human cytomegalovirus immediate-early
promoter.
Stapled TM peptides modulate GPCR oligomers
27
Figure 3. Assay optimisation for the screening of peptides disrupting 5-HT2AR-CB1R heteromers.
(A) Schematic representation of the CMV-driven NanoBiT N-terminally tagged CB1 and 5-HT2A
receptors. Comparison between N-terminal or C-terminal tagging to assess CB1R and 5-HT2A receptors
homomers (B) or 5-HT2AR-CB1R heteromers (C). Data are mean ± SEM (n = 3) of fold change,
calculated as the ratio between each condition and the individual receptor construct with the highest
luminescence background. Statistical significance was evaluated by unpaired t-tests between groups
followed by Holk-Sidak corrections for multiple comparison (*p ≤0.05,****p ≤0.0001). CMV, human
cytomegalovirus immediate-early promoter.
Stapled TM peptides modulate GPCR oligomers
28
Stapled TM peptides modulate GPCR oligomers
29
Figure 4. Biophysical Analysis of Stapled Peptides (A) Amino acid sequence alignment of the targeted
TM regions and disrupting peptides. Cys are in reduced state. Blue bridges indicate the stapled amino acid
residues. HIV-TAT amino acid sequence is displayed in red. Yields, purity and MALDI-TOF data shown
for the stapled peptides and negative control. (B) Circular dichroism analysis of 30-50 μM peptides at
20°C. For proteolytic stability studies, the peptides solution (55.5 μM for trypsin and chymotrypsin and
11.1 μM for serum) were incubated in the presence of 0.55 μg/mL of trypsin from porcine pancreas (E),
α-chymotrypsin (F) or mouse serum (G) at 37 °C for the indicated times (see figure legends). Data are
mean ± SEM (n = 3) percentage of intact peptide normalised to t=0. Proteolytic half-lives and putative
cleavage sites (predicted using Expasy bioinformatics server’s model with the 50% probability of
cleavage) are indicated in the bottom panels of each figure. Positive correlation between helicity and half-
life in trypsin/chymotrypsin (C) or serum (D) was determined by two-tailed Pearson’s correlation test.
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Figure 5. Identification of a small-stapled TM peptide disrupting 5-HT2AR-CB1R heteromers. (A)
Schematic representation of the NanoBiT assay using N-terminally labelled constructs. In (B), HEK-293
cells transiently expressing the LgBT-CB1R and SmBiT- 5-HT2AR complementary pairs were pre-
incubated for 1h at 37°C with the indicated peptides (4 μM) or vehicle prior to luminescence recording.
Data are mean RLU ± SEM (n ≥ 5) percentage of luminescence normalised to vehicle-treated cells.
Statistical significance was evaluated by one-way analysis of variance (ANOVA) followed by Bonferroni
post hoc tests, indicating significant differences over vehicle-treated cells (, ***p ≤0.001, ****p ≤0.0001)
and for peptide 10 over its related peptides (####p ≤0.0001). Peptide 10 potency (C) was evaluated as in A
over increasing peptide concentrations (see figure legends) (n=3). Alternatively, to assess the kinetics of
the peptide 10-driven heteromer disruption (D), prior to the administration of the peptide (see figure
legends), the cells were pre-incubated with substrate and the luminescence was recorded over the
following 30 min. Data are mean RLU ± SEM (n ≥ 3) percentage of luminescence normalised to vehicle
treated cells.
